Clinical trial NCT01313377: Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
Official title: Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Liver Cancer
Keywords: adenocarcinoma of the extrahepatic bile duct
cholangiocarcinoma of the extrahepatic bile duct
liver and intrahepatic biliary tract cancer
localized extrahepatic bile duct cancer
adenocarcinoma of the gallbladder
cholangiocarcinoma of the gallbladder
localized gallbladder cancer
Lead sponsor: UNICANCER
Sponsor class: OTHER
First posted: 2011-03-11
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Observation is watching a patient's condition but not giving treatment until symptoms appear. It is not yet known whether giving gemcitabine hydrochloride together with oxaliplatin is more effective than observation in treating patients with biliary tract cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying giving gemcitabine hydrochloride together with oxaliplatin to see how well it works compared with observation in treating patients with biliary tract cancer that has been removed by surgery.

Detailed description: OBJECTIVES:

Primary

* Compare disease-free survival (DFS) of patients with resected biliary tract cancer treated with adjuvant gemcitabine hydrochloride and oxaliplatin versus clinical observation.
* Compare quality of life of these patients.

Secondary

* Compare overall survival of these patients.
* Determine the toxicity of the chemotherapy in these patients.
* Explore prognostic factors for DFS including resection result (R0 vs R1), location of primary tumor (intrahepatic vs extrahepatic vs gallbladder), evolution of CA19-9, and lymph node involvement (N0 vs N+ and Nx). (Exploratory)
* Study pathological factors in surgical specimens to identify main characteristics and phenotypic clinicoanatomical biliary tract cancers before therapy. (Exploratory)
* Identify nontumor-associated liver injury and factors that may facilitate the emergence of biliary tract cancers. (Exploratory)
* Identify signaling pathways that may predict response to therapy. (Exploratory)
* Determine the molecular characteristics to differentiate tumors according to their position in the biliary tract (extrahepatic bile duct, intrahepatic cholangiocarcinoma site \[hilar\], and peripheral cholangiocarcinoma vesicle site). (Exploratory)

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 14 days for 12 courses.
* Arm II: Patients undergo clinical observation only every 4 weeks for 5 months. Quality of life is assessed at baseline, at 3 and 6 months, and then at all follow-up visits.

After completion of study therapy, patients are followed up at 6 months, every 3 months for 2 years, and then every 6 months for 3 years.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically proven adenocarcinoma of the intrahepatic bile ducts, gallbladder, or extrahepatic bile ducts

  * Mixed forms of hepatocholangiocarcinomas included provided the cholangiocarcinoma is predominant
* Underwent surgical resection of the disease (R0 or R1) at least 4 weeks but no more than 13 weeks ago
* Nonmetastatic disease as assessed by abdominal MRI and chest x-ray
* No cancer of the pancreas or duodenum invading the bile duct and ampulla of Vater

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Hemoglobin ≥ 10 g/dL (transfusion allowed)
* ANC ≥ 1,500/mm³
* Platelet count ≥ 75,000/mm³
* Creatinine clearance \> 40 mL/min
* Prothrombin time \> 60% OR INR \< 1.5 (without anticoagulant therapy)
* Transaminases ≤ 5 times upper limit of normal (ULN)
* Alkaline phosphatase ≤ 2.5 times ULN
* Conjugated bilirubin ≤ 35 μmol/L (after biliary drainage, if necessary)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No contraindications to oxaliplatin and gemcitabine hydrochloride therapy
* Prior invasive cancer allowed provided it has been in complete remission for ≥ 5 years
* No other concurrent invasive cancer except adequately treated carcinoma in situ of the cervix or basal cell carcinoma
* No other severe, unresolved disease
* No mental illness
* No HIV positivity
* No grade 1 angina or symptomatic angina ≥ grade 2
* No sensitive peripheral neuropathy
* No uncontrolled diabetes
* No inability to undergo medical tests due to geographical, social, or psychological reasons
* No prisoners or patients under guardianship
* No Child B or C cirrhosis

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior neoadjuvant chemotherapy or radiotherapy
* No prior organ transplantation
* No concurrent participation in another clinical trial of an experimental agent

Primary outcomes:
measure: Disease-free survival
timeFrame: up to 3 years
measure: Quality of life
timeFrame: up to 3 years
Secondary outcomes:
measure: Overall survival
timeFrame: up to 3 years
measure: Toxicity of adjuvant chemotherapy
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU - Hôpital Nord
city: Angers
country: France
facility: Centre Paul Papin
city: Avignon
country: France
facility: Institut Sainte Catherine
city: Bayonne
country: France
facility: Centre hospitalier de la Côte Basque
city: Besancon
country: France
facility: Hôpital Jean Minjoz
city: Bobigny
country: France
facility: Hôpital Avicenne
city: Brest
country: France
facility: CHU Brest - Hôpital Morvan
city: Caen
country: France
facility: CHU Côte de Nacre
city: Clermont Ferrand
country: France
facility: CHU Estaing
city: Clichy
country: France
facility: Hôpital Beaujon
city: Créteil
country: France
facility: Hôpital Henri Mondor
city: Dijon
country: France
facility: Hôpital Bocage
city: La Roche Sur Yon
country: France
facility: CHD Vendée
city: Lyon
country: France
facility: Centre Léon Bérard
city: Lyon
country: France
facility: Hôpital Privé Jean Mermoz
city: Lyon
country: France
facility: Hôpital Edouard Herriot
city: Marseille
country: France
facility: Hôpital Saint Joseph
city: Marseille
country: France
facility: Hôpital Nord
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Marseille
country: France
facility: CHU Timone Adulte
city: Montpellier
country: France
facility: Centre Hospitalier Saint Eloi
city: Nantes
country: France
facility: Centre René Gauducheau
city: Orléans
country: France
facility: Hôpital La Source
city: Paris
country: France
facility: Hôpital Saint Antoine
city: Paris
country: France
facility: Institut Mutualiste Montsouris
city: Paris
country: France
facility: CHU Saint Louis
city: Paris
country: France
facility: Hôpital de la Pitié Salpétrière
city: Paris
country: France
facility: Hôpital Européen Georges Pompidou
city: Poitiers
country: France
facility: CHU de Poitiers
city: Rennes
country: France
facility: Centre Eugene Marquis
city: Rouen
country: France
facility: CHU de Rouen - Hôpital Ch. Nicolle
city: Sainte-Etienne
country: France
facility: CHU Sainte-Etienne - Hopital Nord
city: Strasbourg
country: France
facility: Centre Paul Strauss
city: Strasbourg
country: France
facility: Hôpital de Hautepierre / Hôpital Civil
city: Tours
country: France
facility: Hôpital Trousseau
city: Vandouevre Les Nancy
country: France
facility: CHU Brabois
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Centre Eugene Marquis
name: Eveline Boucher, MD
role: PRINCIPAL_INVESTIGATOR
References: